UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001627
Receipt number R000001934
Scientific Title Efficacy of addition of HB vaccine in patients with chronic hepatitis B who are still HBeAg-positive after one year of entecavir administration: a randomized controlled trial
Date of disclosure of the study information 2013/03/31
Last modified on 2014/11/06 09:18:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of addition of HB vaccine in patients with chronic hepatitis B who are still HBeAg-positive after one year of entecavir administration: a randomized controlled trial

Acronym

Entecavir plus HB vaccine combination trial

Scientific Title

Efficacy of addition of HB vaccine in patients with chronic hepatitis B who are still HBeAg-positive after one year of entecavir administration: a randomized controlled trial

Scientific Title:Acronym

Entecavir plus HB vaccine combination trial

Region

Japan


Condition

Condition

HBeAg-positive chronic hepatitis B

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the safety and efficacy of addition of HB vaccine in patients with chronic hepatitis B who are still HBeAg-positive after one year of entecavir administration

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

negative HBeAg, undetectable HBV DNA, and normal ALT at month 12 of entecavir plus HB vaccine combination therapy

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Vaccine

Interventions/Control_1

Continue oral entecavir administration at a daily dose of 0.5 mg for 12 months

Interventions/Control_2

Add HB vaccine (to entecavir) by intramuscular injection at a monthly dose of 10 microg for 12 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.persistent or fluctuating elevations of serum ALT for at least 6 months before the start of entecavir
2.positive HBeAg before the start of entecavir
3.detectable HBV DNA before the start of entecavir
4.still HBeAg-positive after one year of entecavir administration

Key exclusion criteria

1.use of lamivudine or any other nucleos(t)ide analogues for hepatitis B
2.use of immunosuppressive or immunomodulatory drugs
3.presence of HCV infection and other likely causes of chronic liver disease
4.clinical signs of decompensated cirrhosis or liver failure
5.severe complication (poor renal, cardiac, or respiratory function)
6.women who are possibly pregnant, expectant mothers, and lactating mothers

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akihiro Tamori

Organization

Osaka City University Graduate School of Medicine

Division name

Department of Hepatology

Zip code


Address

1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, JAPAN

TEL

06-6645-3811

Email

atamori@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akihiro Tamori

Organization

Osaka City University Graduate School of Medicine

Division name

Department of Hepatology

Zip code


Address

1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, JAPAN

TEL

06-6645-3435

Homepage URL


Email

atamori@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

The present study showed that HB vaccine therapy did not have anti-HBV effect for patients with entecavir poor response.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2008 Year 11 Month 01 Day

Last follow-up date

2013 Year 03 Month 01 Day

Date of closure to data entry

2014 Year 07 Month 31 Day

Date trial data considered complete

2014 Year 08 Month 31 Day

Date analysis concluded

2014 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2009 Year 01 Month 07 Day

Last modified on

2014 Year 11 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001934


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name